Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Perspective TherapeuticsFRA:AAJ0 -9.08%33 Gross Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:AAJ0 with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 806 Medical Devices & Instruments companies, Perspective Therapeutics ranks worse than 124069.35% on this metric.
FRA:AAJ0's Gross Margin % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 52.115 * Ranked among companies with meaningful Gross Margin % only.
Perspective Therapeutics had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Perspective Therapeutics had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Perspective Therapeutics Gross Margin % Related Terms
Perspective Therapeutics Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AAJ0 vs ELMD, MASS, CV: Gross Margin % Comparison
For the Medical Devices subindustry, Perspective Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perspective Therapeutics Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Perspective Therapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Perspective Therapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Perspective Therapeutics (FRA:AAJ0) has a Gross Margin % of 0.00% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Perspective Therapeutics and its competitors. Over the past decade, Perspective Therapeutics' Gross Margin % has ranged from 2.70 to 52.93. According to the industry distribution chart, Perspective Therapeutics ranks #999999 out of 806 companies in the Medical Devices & Instruments industry.
Is Perspective Therapeutics' Gross Margin % too high?
Perspective Therapeutics' current Gross Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 2.70 to a high of 52.93. Based on the distribution chart, Perspective Therapeutics ranks #999999 out of 806 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Perspective Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Perspective Therapeutics' Gross Margin % compare to ELMD and MASS?
According to the Medical Devices & Instruments industry distribution chart, Perspective Therapeutics ranks #999999 out of 806 companies for Gross Margin %. This places Perspective Therapeutics in the lower half of its industry. The industry median Gross Margin % is 52.12. Historically, Perspective Therapeutics' own Gross Margin % has ranged from 2.70 to 52.93 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.12, based on 806 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Perspective Therapeutics and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perspective Therapeutics's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perspective Therapeutics stock overvalued right now?
Perspective Therapeutics (FRA:AAJ0) has a current Gross Margin % of 0.00%. The current Gross Margin % is 0.00%. Perspective Therapeutics' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Perspective Therapeutics (FRA:AAJ0), the current Gross Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
33GF Score
Get the complete analysis for FRA:AAJ0
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AAJ0 has been successfully added to your 
